Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 146


Oncolytic vesicular stomatitis virus and bortezomib are antagonistic against myeloma cells in vitro but have additive anti-myeloma activity in vivo.

Yarde DN, Nace RA, Russell SJ.

Exp Hematol. 2013 Dec;41(12):1038-49. doi: 10.1016/j.exphem.2013.09.005. Epub 2013 Sep 22.


Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-β.

Naik S, Nace R, Barber GN, Russell SJ.

Cancer Gene Ther. 2012 Jul;19(7):443-50. doi: 10.1038/cgt.2012.14. Epub 2012 Apr 20.


Histone deacetylase inhibitors potentiate vesicular stomatitis virus oncolysis in prostate cancer cells by modulating NF-κB-dependent autophagy.

Shulak L, Beljanski V, Chiang C, Dutta SM, Van Grevenynghe J, Belgnaoui SM, Nguyên TL, Di Lenardo T, Semmes OJ, Lin R, Hiscott J.

J Virol. 2014 Mar;88(5):2927-40. doi: 10.1128/JVI.03406-13. Epub 2013 Dec 26.


Vesicular stomatitis virus-induced immune suppressor cells generate antagonism between intratumoral oncolytic virus and cyclophosphamide.

Willmon C, Diaz RM, Wongthida P, Galivo F, Kottke T, Thompson J, Albelda S, Harrington K, Melcher A, Vile R.

Mol Ther. 2011 Jan;19(1):140-9. doi: 10.1038/mt.2010.224. Epub 2010 Oct 26.


Radioiodide imaging and radiovirotherapy of multiple myeloma using VSV(Delta51)-NIS, an attenuated vesicular stomatitis virus encoding the sodium iodide symporter gene.

Goel A, Carlson SK, Classic KL, Greiner S, Naik S, Power AT, Bell JC, Russell SJ.

Blood. 2007 Oct 1;110(7):2342-50. Epub 2007 May 21.


Oncolytic measles and vesicular stomatitis virotherapy for endometrial cancer.

Liu YP, Steele MB, Suksanpaisan L, Federspiel MJ, Russell SJ, Peng KW, Bakkum-Gamez JN.

Gynecol Oncol. 2014 Jan;132(1):194-202. doi: 10.1016/j.ygyno.2013.11.010. Epub 2013 Nov 15.


Triptolide-mediated inhibition of interferon signaling enhances vesicular stomatitis virus-based oncolysis.

Ben Yebdri F, Van Grevenynghe J, Tang VA, Goulet ML, Wu JH, Stojdl DF, Hiscott J, Lin R.

Mol Ther. 2013 Nov;21(11):2043-53. doi: 10.1038/mt.2013.187. Epub 2013 Aug 28.


Variation in susceptibility of human malignant melanomas to oncolytic vesicular stomatitis virus.

Blackham AU, Northrup SA, Willingham M, D'Agostino RB Jr, Lyles DS, Stewart JH 4th.

Surgery. 2013 Mar;153(3):333-43. doi: 10.1016/j.surg.2012.09.003. Epub 2012 Oct 25.


Interleukin-12 expression enhances vesicular stomatitis virus oncolytic therapy in murine squamous cell carcinoma.

Shin EJ, Wanna GB, Choi B, Aguila D 3rd, Ebert O, Genden EM, Woo SL.

Laryngoscope. 2007 Feb;117(2):210-4.


Amalgamating oncolytic viruses to enhance their safety, consolidate their killing mechanisms, and accelerate their spread.

Ayala-Breton C, Suksanpaisan L, Mader EK, Russell SJ, Peng KW.

Mol Ther. 2013 Oct;21(10):1930-7. doi: 10.1038/mt.2013.164. Epub 2013 Jul 11.


Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia.

Shen W, Patnaik MM, Ruiz A, Russell SJ, Peng KW.

Blood. 2016 Mar 17;127(11):1449-58. doi: 10.1182/blood-2015-06-652503. Epub 2015 Dec 28.


Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells.

Hideshima T, Ikeda H, Chauhan D, Okawa Y, Raje N, Podar K, Mitsiades C, Munshi NC, Richardson PG, Carrasco RD, Anderson KC.

Blood. 2009 Jul 30;114(5):1046-52. doi: 10.1182/blood-2009-01-199604. Epub 2009 May 12.


Semireplication-competent vesicular stomatitis virus as a novel platform for oncolytic virotherapy.

Muik A, Dold C, Geiß Y, Volk A, Werbizki M, Dietrich U, von Laer D.

J Mol Med (Berl). 2012 Aug;90(8):959-70. doi: 10.1007/s00109-012-0863-6.


Interferon Beta and Interferon Alpha 2a Differentially Protect Head and Neck Cancer Cells from Vesicular Stomatitis Virus-Induced Oncolysis.

Westcott MM, Liu J, Rajani K, D'Agostino R Jr, Lyles DS, Porosnicu M.

J Virol. 2015 Aug;89(15):7944-54. doi: 10.1128/JVI.00757-15. Epub 2015 May 20.


Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-kappaB activity in myeloma cells.

Markovina S, Callander NS, O'Connor SL, Xu G, Shi Y, Leith CP, Kim K, Trivedi P, Kim J, Hematti P, Miyamoto S.

Mol Cancer. 2010 Jul 6;9:176. doi: 10.1186/1476-4598-9-176.


Norcantharidin enhances bortezomib-antimyeloma activity in multiple myeloma cells in vitro and in nude mouse xenografts.

Du HF, Yu LJ, Meng YF, Lv HY, Meng J, Song XN, Zhang JQ.

Leuk Lymphoma. 2013 Mar;54(3):607-18. doi: 10.3109/10428194.2012.720371. Epub 2012 Sep 3.


PEGylation of vesicular stomatitis virus extends virus persistence in blood circulation of passively immunized mice.

Tesfay MZ, Kirk AC, Hadac EM, Griesmann GE, Federspiel MJ, Barber GN, Henry SM, Peng KW, Russell SJ.

J Virol. 2013 Apr;87(7):3752-9. doi: 10.1128/JVI.02832-12. Epub 2013 Jan 16. Erratum in: J Virol. 2015 Feb;89(4):2453.


Bortezomib-enhanced radiosensitization through the suppression of radiation-induced nuclear factor-κB activity in human oral cancer cells.

Tamatani T, Takamaru N, Hara K, Kinouchi M, Kuribayashi N, Ohe G, Uchida D, Fujisawa K, Nagai H, Miyamoto Y.

Int J Oncol. 2013 Mar;42(3):935-44. doi: 10.3892/ijo.2013.1786. Epub 2013 Jan 22.


Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus.

Galivo F, Diaz RM, Thanarajasingam U, Jevremovic D, Wongthida P, Thompson J, Kottke T, Barber GN, Melcher A, Vile RG.

Hum Gene Ther. 2010 Apr;21(4):439-50. doi: 10.1089/hum.2009.143.


The vesicular stomatitis virus matrix protein inhibits NF-κB activation in mouse L929 cells.

Varble AJ, Ried CD, Hammond WJ, Marquis KA, Woodruff MC, Ferran MC.

Virology. 2016 Dec;499:99-104. doi: 10.1016/j.virol.2016.09.009. Epub 2016 Sep 17.


Supplemental Content

Support Center